← All trials

NCT06754085

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Dec 19, 2024
Primary completion
Jan 1, 2026
Completion date
May 1, 2026
First posted
Dec 31, 2024
Last posted
Dec 31, 2024
Enrollment
131
Arms / groups
1 / —
Source
AACT · ctgov ingestion

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.